Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 6326 - 6350 of 8179 in total
SHR-A1904 is under investigation in clinical trial NCT04877717 (A Study of SHR-A1904 in Patients With Advanced Solid Cancer).
Investigational
Matched Description: … SHR-A1904 is under investigation in clinical trial NCT04877717 (A Study of SHR-A1904 in Patients With …
Acapatamab is under investigation in clinical trial NCT04631601 (Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (Mcrpc)).
Investigational
Matched Description: … Acapatamab is under investigation in clinical trial NCT04631601 (Safety and Efficacy of Therapies for …
Zeluvalimab is under investigation in clinical trial NCT04631601 (Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (Mcrpc)).
Investigational
Matched Description: … Zeluvalimab is under investigation in clinical trial NCT04631601 (Safety and Efficacy of Therapies for …
ANC-501 is under investigation in clinical trial NCT05439603 (ANC-501 in the Treatment of Adults With Major Depressive Disorder).
Investigational
Matched Description: … ANC-501 is under investigation in clinical trial NCT05439603 (ANC-501 in the Treatment of Adults With …
Lonigutamab is under investigation in clinical trial NCT05683496 (Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)).
Investigational
Matched Description: … Lonigutamab is under investigation in clinical trial NCT05683496 (Efficacy and Safety of Lonigutamab …
Lorundrostat is under investigation in clinical trial NCT06153693 (Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension).
Investigational
Matched Description: … Lorundrostat is under investigation in clinical trial NCT06153693 (Efficacy and Safety of Lorundrostat …
Plozasiran is under investigation in clinical trial NCT05089084 (Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)).
Investigational
Matched Description: … Plozasiran is under investigation in clinical trial NCT05089084 (Study of ARO-APOC3 (Plozasiran) in Adults …
Putrescine is a toxic diamine formed by putrefaction from the decarboxylation of arginine and ornithine. Putrescine is a solid. This compound belongs to the polyamines. These are compounds containing more than one amine group. Known drug targets of putrescine include putrescine-binding periplasmic protein, ornithine decarboxylase, and S-adenosylmethionine decarboxylase proenzyme.
Experimental
Matched Description: … Putrescine is a toxic diamine formed by putrefaction from the decarboxylation of arginine and ornithine ... Known drug targets of putrescine include putrescine-binding periplasmic protein, ornithine decarboxylase …
MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
Investigational
Matched Description: … MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis ... regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of
PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha.
Investigational
Matched Description: … PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical ... PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express …
MDI-P has demonstrated potent anti-HIV activity. MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF").
Investigational
Matched Description: … MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF …
Quaternium-18 is a mixture of quaternary ammonium chloride salts. Quaternium-18 Hectorite and Bentonite are the reaction products of Quaternium-18 with clays. These compounds are poorly absorbed through the skin. Acute oral and percutaneous toxicity tests in animals indicate that they exhibit little or no systemic toxic effects.
Experimental
Matched Description: … Quaternium-18 is a mixture of quaternary ammonium chloride salts. ... Quaternium-18 Hectorite and Bentonite are the reaction products of Quaternium-18 with clays. …
Alfaxalone, also known as alphaxalone or alphaxolone, is a neuroactive steroid and general anaesthetic. It is used in veterinary practice under the trade name Alfaxan, and is licensed for use in both dogs and cats. Along with alfadolone, it is also one of the constituents of anesthetic drug mixture althesin.
Vet approved
Matched Description: … Along with alfadolone, it is also one of the constituents of anesthetic drug mixture althesin. …
Phosphorus P-32 is a radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity. Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular biological macromolecules, resulting in tumor cell death.
Experimental
Matched Description: … Phosphorus P-32 is a radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity ... particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of
Avasopasem manganese, also known as GC4419, is a highly-selective small molecule mimetic of superoxide dismutase (SOD) being investigated for the reduction of radiation-induced severe oral mucositis.[L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis, in addition to being currently tested against COVID-19.
Investigational
Matched Description: … Avasopasem manganese, also known as GC4419, is a highly-selective small molecule mimetic of superoxide ... dismutase (SOD) being investigated for the reduction of radiation-induced severe oral mucositis. …
V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings. Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both prior...
Investigational
Matched Description: … V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative …
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the...
Experimental
Investigational
Matched Description: … icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). ... Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of
Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal...
Investigational
Matched Description: … Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer ... Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube …
LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which are based on domains of selected viral proteins. This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs). As of August 2020, this vaccine...
Investigational
Matched Description: … cells that are modified with lentiviral vector-expressing synthetic minigene which are based on domains of ... As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials …
The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India . The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest . Once the plasmid DNA is introduced into host cells and the viral protein is translated,...
Investigational
Matched Description: … As of August, 2020 the candidate is in Phase II clinical trials[A219758]. ... using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of ... is translated, it elicits a strong immune response, stimulating the humoral and cellular components of
TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer. It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine. Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil...
Investigational
Matched Description: … USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of ... It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine …
Malacidin A, along with DB14052, is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria . Malacidins are 10-member macrocycle lipopeptides discovered via gene sequencing and bioinformatic analysis. While structurally similar to other macrocycle drugs like DB00080 and DB06087, Malacidin A...
Experimental
Matched Description: … Malacidin A, along with [DB14052], is a member of a class of chemicals made by bacteria found in soil …
Malacidin B, along with DB14051, is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria . Malacidins are 10-member macrocycle lipopeptides discovered via gene sequencing and bioinformatic analysis. While structurally similar to other macrocycle drugs like DB00080 and DB06087, Malacidin B...
Experimental
Matched Description: … Malacidin B, along with [DB14051], is a member of a class of chemicals made by bacteria found in soil …
A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used...
Experimental
Matched Description: … It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid …
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … Phase 1 clinical trials of this vaccine (NCT04449276). ... As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence …
Displaying drugs 6326 - 6350 of 8179 in total